MX2017011794A - Composiciones y metodos para diagnosticos y tratamiento del cancer. - Google Patents
Composiciones y metodos para diagnosticos y tratamiento del cancer.Info
- Publication number
- MX2017011794A MX2017011794A MX2017011794A MX2017011794A MX2017011794A MX 2017011794 A MX2017011794 A MX 2017011794A MX 2017011794 A MX2017011794 A MX 2017011794A MX 2017011794 A MX2017011794 A MX 2017011794A MX 2017011794 A MX2017011794 A MX 2017011794A
- Authority
- MX
- Mexico
- Prior art keywords
- diagnostics
- compositions
- methods
- cancer treatment
- seprase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
Abstract
La presente invención se relaciona con el diagnóstico y tratamiento de enfermedades cancerosas, en particular enfermedades cancerosas que expresan Seprase (Fap-alfa; proteína alfa para activación de fibroblastos). Más particularmente, la invención se relaciona con péptidos que se focalizan a Seprase.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2015/055560 WO2016146174A1 (en) | 2015-03-17 | 2015-03-17 | Compositions and methods for diagnosis and treatment of cancer |
| PCT/EP2016/055601 WO2016146639A1 (en) | 2015-03-17 | 2016-03-15 | Compositions and methods for diagnosis and treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017011794A true MX2017011794A (es) | 2018-02-19 |
| MX377781B MX377781B (es) | 2025-03-11 |
Family
ID=52684233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011794A MX377781B (es) | 2015-03-17 | 2016-03-15 | Composiciones y metodos para diagnostico y tratamiento del cancer. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10370433B2 (es) |
| EP (1) | EP3271385B1 (es) |
| JP (1) | JP6739132B2 (es) |
| KR (1) | KR102414718B1 (es) |
| CN (1) | CN107531776B (es) |
| AU (1) | AU2016232301B2 (es) |
| CA (1) | CA2979768C (es) |
| ES (1) | ES2747727T3 (es) |
| MX (1) | MX377781B (es) |
| WO (2) | WO2016146174A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2972577T3 (es) | 2016-12-14 | 2024-06-13 | Purdue Research Foundation | Formación de imágenes y terapia dirigidas a la proteína de activación de fibroblastos (FAP) |
| WO2019233605A1 (en) * | 2018-06-08 | 2019-12-12 | BioNTech SE | Compositions and methods for diagnosis and treatment of cancer |
| GB201820320D0 (en) * | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for FAPalpha |
| CN114269770B (zh) | 2019-07-03 | 2025-02-25 | 肽梦想株式会社 | Cd38结合剂及其用途 |
| EP3763726A1 (en) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| KR20220032078A (ko) | 2019-07-08 | 2022-03-15 | 쓰리비 파마슈티컬스 게엠베하 | 섬유모세포 활성화 단백질 리간드를 포함하는 화합물 및 그의 용도 |
| US12427210B2 (en) | 2019-07-08 | 2025-09-30 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CN112409414B (zh) * | 2020-12-01 | 2021-10-26 | 北京师范大学 | 锝-99m标记含异腈的FAPI衍生物及制备方法和应用 |
| AU2022205523A1 (en) | 2021-01-07 | 2023-07-13 | 3B Pharmaceuticals Gmbh | Compounds comprising a fibroblast activation protein ligand and use thereof |
| EP4050018A1 (en) * | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Compounds comprising a fibroblast activation protein ligand and use thereof |
| CA3236054A1 (en) * | 2021-11-29 | 2023-06-01 | Eva BOSSE-DOENECKE | Specific binding molecules for fibroblast activation protein (fap) |
| KR20250143347A (ko) * | 2023-02-10 | 2025-10-01 | 청두 뉴 라디오메디슨 테크놀로지 컴퍼니 리미티드 | 폴리펩타이드 화합물 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0907887A4 (en) * | 1996-03-20 | 2002-10-30 | Dyax Corp | Affinity ligands for macromolecules obtained through genetic manipulation |
| US6884770B1 (en) * | 1998-11-06 | 2005-04-26 | Curis, Inc. | Methods and compositions for treating or preventing peripheral neuropathies |
| US6951839B1 (en) * | 1999-11-30 | 2005-10-04 | Curis, Inc. | Methods and compositions for regulating lymphocyte activity |
| CA2580881A1 (en) * | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag | Use of microproteins as tryptase inhibitors |
| US7374898B2 (en) * | 2004-10-12 | 2008-05-20 | The Research Foundation Of State University Of New York | Peptide inhibitors against seprase |
| ES2417153T5 (es) * | 2006-03-06 | 2024-04-04 | Amunix Operating Inc | Polímeros recombinantes no estructurados y usos de los mismos |
| MX2010004671A (es) * | 2007-12-10 | 2010-05-27 | Hoffmann La Roche | Seprasa como marcador para cancer. |
| US9034383B2 (en) * | 2010-08-23 | 2015-05-19 | NanoRx, Inc. | Policosanol nanoparticles |
| CN102643847A (zh) * | 2011-02-17 | 2012-08-22 | 华东理工大学 | 多基因共表达体系及含二硫键功能性蛋白的生产方法 |
| US20150293120A1 (en) * | 2012-03-27 | 2015-10-15 | Protagen Ag | Marker sequences for rheumatoid arthritis |
| GB201218278D0 (en) * | 2012-10-11 | 2012-11-28 | Cyclogenix Ltd | Translocating peptide |
-
2015
- 2015-03-17 WO PCT/EP2015/055560 patent/WO2016146174A1/en not_active Ceased
-
2016
- 2016-03-15 CA CA2979768A patent/CA2979768C/en active Active
- 2016-03-15 US US15/552,215 patent/US10370433B2/en active Active
- 2016-03-15 AU AU2016232301A patent/AU2016232301B2/en active Active
- 2016-03-15 ES ES16712761T patent/ES2747727T3/es active Active
- 2016-03-15 KR KR1020177026055A patent/KR102414718B1/ko active Active
- 2016-03-15 WO PCT/EP2016/055601 patent/WO2016146639A1/en not_active Ceased
- 2016-03-15 JP JP2017549007A patent/JP6739132B2/ja active Active
- 2016-03-15 CN CN201680015916.1A patent/CN107531776B/zh active Active
- 2016-03-15 MX MX2017011794A patent/MX377781B/es active IP Right Grant
- 2016-03-15 EP EP16712761.2A patent/EP3271385B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102414718B1 (ko) | 2022-06-30 |
| ES2747727T3 (es) | 2020-03-11 |
| CA2979768C (en) | 2022-07-05 |
| AU2016232301A1 (en) | 2017-09-07 |
| JP2018515066A (ja) | 2018-06-14 |
| CN107531776A (zh) | 2018-01-02 |
| WO2016146174A1 (en) | 2016-09-22 |
| WO2016146639A1 (en) | 2016-09-22 |
| MX377781B (es) | 2025-03-11 |
| BR112017018522A2 (en) | 2018-04-17 |
| AU2016232301B2 (en) | 2020-12-24 |
| EP3271385B1 (en) | 2019-07-03 |
| NZ734680A (en) | 2022-03-25 |
| CA2979768A1 (en) | 2016-09-22 |
| US20180037632A1 (en) | 2018-02-08 |
| EP3271385A1 (en) | 2018-01-24 |
| US10370433B2 (en) | 2019-08-06 |
| KR20170121215A (ko) | 2017-11-01 |
| HK1247931A1 (zh) | 2018-10-05 |
| CN107531776B (zh) | 2022-01-25 |
| JP6739132B2 (ja) | 2020-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017011794A (es) | Composiciones y metodos para diagnosticos y tratamiento del cancer. | |
| JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
| WO2018190719A3 (en) | Anti-sirp alpha antibodies | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| ZA201905488B (en) | Tigit- and light-based chimeric proteins | |
| PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| CO2018012374A2 (es) | Moléculas de anticuerpo para el tratamiento del cáncer | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| MX2022007522A (es) | Anticuerpos anti-cd27. | |
| SV2017005355A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
| TW201613901A (en) | New compounds | |
| PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
| WO2015009726A3 (en) | Medical uses of cd38 agonists | |
| EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
| PH12021551419A1 (en) | New conjugated nucleic acid molecules and their uses | |
| MA40363A (fr) | Agents de liaison de rspo1 et leurs utilisations | |
| EA201992022A1 (ru) | Терапевтическая рнк | |
| EA201890865A1 (ru) | Средство, обладающее одновременно протекторным действием в отношении здоровых органов и тканей и адъювантным действием при радио- и химиотерапии опухолей | |
| EA202091619A3 (ru) | Антитела против tigit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |